{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001548","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.584465+00:00","generated_at":"2026-06-18T07:27:07.702073+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aligos reports FY2022 net loss of $96M; provides pipeline updates for NASH, COVID-19, HBV","bullets":["Net loss FY2022 $96.0M ($2.25/share) vs $128.3M ($3.22) in FY2021; cash $125.8M as of Dec 31, 2022.","NASH candidate ALG-055009 Phase 1 data positive; on track for Phase 2 filing by end 2023.","COVID-19 candidate ALG-097558 to enter clinic in Q2 2023; top line data expected Q4 2023.","HBV CAM-E ALG-000184 shows HBsAg reductions; 48-week data expected in 2023.","HBV siRNA ALG-125755 SAD in healthy volunteers completed; now evaluating in CHB subjects."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001548","json":"https://secwatch.observer/filing/0001171843-23-001548.json","markdown":"https://secwatch.observer/filing/0001171843-23-001548.md","text":"https://secwatch.observer/filing/0001171843-23-001548.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323001548/0001171843-23-001548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323001548/f8k_030923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:27:07.702073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99a58efcebc34d3ef26a8ba6bf18d5e1c1068ee9","claim":"Aligos Therapeutics, Inc. reported the fourth quarter and full year 2022 results: net income Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common sha, EPS $(0.51).","evidence_excerpt":"Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common share of $(0.51), compared to net losses of $37.7 million or basic and diluted net loss per common share of $(0.89) for the three months ended December 31, 2021. Net losses for the year ended December 31, 2022, were $96.0 million or basic and diluted net loss per common share of $(2.25), compared to net losses of $128.3 million or basic and diluted net loss per common share of $(3.22) for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323001548/0001171843-23-001548-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2022"},{"label":"Net income","value":"Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common sha"},{"label":"EPS","value":"$(0.51)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}